LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Hutchison China MediTech Ltd ADR

Закрыт

СекторЗдравоохранение

16.35 3.68

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

16.18

Макс.

16.37

Ключевые показатели

By Trading Economics

Доход

6M

Продажи

162M

P/E

Средняя по отрасли

5.842

34.427

Рентабельность продаж

3.676

Сотрудники

1,780

EBITDA

-5M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+29.18% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.7B

Предыдущая цена открытия

12.67

Предыдущая цена закрытия

16.35

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 авг. 2025 г., 16:11 UTC

Главные движущие силы рынка

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 авг. 2025 г., 22:22 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

15 авг. 2025 г., 22:22 UTC

Обсуждения рынка

Target Is Falling Behind Its Peers -- Market Talk

15 авг. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

15 авг. 2025 г., 20:33 UTC

Обсуждения рынка

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 авг. 2025 г., 20:25 UTC

Отчет
Приобретения, слияния, поглощения

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 авг. 2025 г., 20:24 UTC

Отчет
Приобретения, слияния, поглощения

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 авг. 2025 г., 20:18 UTC

Отчет

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 авг. 2025 г., 19:14 UTC

Обсуждения рынка

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 авг. 2025 г., 19:12 UTC

Обсуждения рынка

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 авг. 2025 г., 18:32 UTC

Обсуждения рынка

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 авг. 2025 г., 17:33 UTC

Обсуждения рынка

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 авг. 2025 г., 17:23 UTC

Обсуждения рынка
Отчет

Deere's Earnings Appear to Be Troughing -- Market Talk

15 авг. 2025 г., 16:27 UTC

Отчет

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 авг. 2025 г., 16:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

15 авг. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

15 авг. 2025 г., 16:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

15 авг. 2025 г., 16:05 UTC

Приобретения, слияния, поглощения

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 авг. 2025 г., 15:52 UTC

Приобретения, слияния, поглощения

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 авг. 2025 г., 15:36 UTC

Обсуждения рынка

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 авг. 2025 г., 15:29 UTC

Отчет

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 авг. 2025 г., 15:29 UTC

Приобретения, слияния, поглощения

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 авг. 2025 г., 15:28 UTC

Отчет

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 авг. 2025 г., 15:24 UTC

Обсуждения рынка

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 авг. 2025 г., 15:08 UTC

Обсуждения рынка

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 авг. 2025 г., 14:38 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 авг. 2025 г., 14:37 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 авг. 2025 г., 14:37 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 авг. 2025 г., 14:36 UTC

Приобретения, слияния, поглощения

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 авг. 2025 г., 14:33 UTC

Приобретения, слияния, поглощения

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Сравнение c конкурентами

Изменение цены

Hutchison China MediTech Ltd ADR Прогноз

Целевая цена

By TipRanks

29.18% рост

Прогноз на 12 месяцев

Средняя 21.25 USD  29.18%

Максимум 25 USD

Минимум 17.5 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Hutchison China MediTech Ltd ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

14.24 / 14.78Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.